Literature DB >> 29774142

Comparison of MRI and 123I-FP-CIT SPECT for the evaluation of MSA-P clinical severity.

Miki Nishimori1, Yoriko Murata1, Hitomi Iwasa1, Kana Miyatake1, Michiko Tadokoro1, Shino Kohsaki2, Munenobu Nogami3, Norihiko Hamada4, Hitoshi Ninomiya5, Yasushi Osaki6, Hirokazu Furuya6, Takuji Yamagami1.   

Abstract

The aim of the present study was to compare the efficacy of magnetic resonance imaging (MRI) and 123I-labeled 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane single photon emission computed tomography (123I-FP-CIT SPECT) for determining the clinical severity of patients with multiple system atrophy with Parkinsonism (MSA-P). MRI and 123I-FP-CIT SPECT images from 17 patients with MSA-P as diagnosed using the Unified MSA Rating Scale part IV (UMSARS IV) score were compared. Brain MRI scans were available for all 17 patients and 123I-FP-CIT SPECT images were available for 12 patients. Putaminal atrophy (PA), hyperintense putaminal rim (HPR), hyperintense pons (hot cross bun sign, HCB), atrophy of the cerebellar vermis and hemisphere (cerebellar atrophy, CA) and other abnormalities were evaluated in the MRI scans. Distribution of striatal uptake (SU) and the specific binding ratio (SBR) on each side of the bilateral striatum were evaluated using 123I-FP-CIT SPECT images. No significant associations were observed between HPR, HCB, CA and UMSARS IV score. However, the frequency of PA increased significantly with higher UMSARS IV score (P<0.05). No significant association was observed between UMSARS IV score and SBR. The results of the present study suggest that PA, which is known to be a diagnostic indicator for MSA-P, may be used to determine the clinical severity of MSA-P with greater efficacy than other MRI findings, including HPR, HCB and CA and 123I-FP-CIT SPECT results.

Entities:  

Keywords:  123I-labeled 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography; clinical severity; magnetic resonance imaging; multiple system atrophy with Parkinsonism

Year:  2018        PMID: 29774142      PMCID: PMC5954600          DOI: 10.3892/br.2018.1086

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  27 in total

1.  Presynaptic and postsynaptic nigrostriatal dopaminergic functions in multiple system atrophy.

Authors:  Masaya Hashimoto; Keiichi Kawasaki; Masahiko Suzuki; Kazuko Mitani; Shigeo Murayama; Masahiro Mishina; Keiichi Oda; Yuichi Kimura; Kiichi Ishiwata; Kenji Ishii; Kiyoharu Inoue
Journal:  Neuroreport       Date:  2008-01-22       Impact factor: 1.837

2.  Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts.

Authors:  Julia Kraemmer; Gabor G Kovacs; Laura Perju-Dumbrava; Susanne Pirker; Tatiana Traub-Weidinger; Walter Pirker
Journal:  Mov Disord       Date:  2014-07-22       Impact factor: 10.338

3.  Differential diagnostic relevance of high resolution magnetic resonance in patients with possible multiple system atrophy (MSA) - A case report.

Authors:  Koraljka Bacić Baronica; Goran Ivkić; David Ozretić; Goran Milicević
Journal:  Coll Antropol       Date:  2011-01

4.  Compton scatter compensation using the triple-energy window method for single- and dual-isotope SPECT.

Authors:  T Ichihara; K Ogawa; N Motomura; A Kubo; S Hashimoto
Journal:  J Nucl Med       Date:  1993-12       Impact factor: 10.057

5.  Clinical features and natural history of multiple system atrophy. An analysis of 100 cases.

Authors:  G K Wenning; Y Ben Shlomo; M Magalhães; S E Daniel; N P Quinn
Journal:  Brain       Date:  1994-08       Impact factor: 13.501

6.  Quantitative CBF measurement using an integrated SPECT/CT system: validation of three-dimensional ordered-subset expectation maximization and CT-based attenuation correction by comparing with O-15 water PET.

Authors:  Eku Shimosegawa; Kouichi Fujino; Hiroki Kato; Jun Hatazawa
Journal:  Ann Nucl Med       Date:  2013-07-04       Impact factor: 2.668

7.  Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.

Authors:  A Antonini; K L Leenders; P Vontobel; R P Maguire; J Missimer; M Psylla; I Günther
Journal:  Brain       Date:  1997-12       Impact factor: 13.501

8.  Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study.

Authors:  Klaus Seppi; Michael F H Schocke; Katherina J Mair; Regina Esterhammer; Christoph Scherfler; Felix Geser; Christian Kremser; Sylvia Boesch; Werner Jaschke; Werner Poewe; Gregor K Wenning
Journal:  Neuroimage       Date:  2006-01-27       Impact factor: 6.556

9.  Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome).

Authors:  M I Papp; J E Kahn; P L Lantos
Journal:  J Neurol Sci       Date:  1989-12       Impact factor: 3.181

10.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.